Erchonia Laser Health Care

2021 Commerce Dr , McKinney- 75069
Texas ,

United States

+1-2145442227 Fax : 2145442228 Toll Free : 8882420571 http://www.erchonia.com

Book Appointment

Timings

Mon - Fri 9:00 AM-5:00 PM

No doctors to show

Erchonia Laser Health Care - McKinney

Erchonia Corporation was founded in 1996 as a small family business, and even though we’ve grown into an international enterprise, we still operate under the founding principles that guided us to our present success. Our commitment to the legitimate advancement of Low Level Laser Therapy (3LT®) through scientific and clinical research has transformed Erchonia into a world leader in the field of LLLT technology. The integrity, diligence, quality and commitment of our company are evident in the rigorous process we follow in order to take a research hypothesis from concept to viable, agency-approved product and treatment method. To ensure a steadfast adherence to our unique all-encompassing approach, our company serves as manufacturer, marketer, developer, promoter, creator and user of all our products.

As manufacturer, we manage to maintain our quality production standards by operating as an 85% self-reliant company. This means we are involved in almost every facet of our products’ creation, performing research, development, fabrication of components and assembly of finished goods all in-house. As marketers, we hold on to the highest customer-service standards possible, providing multi-media training and meeting all of our client’s requests with creativity and purpose. By overseeing the development of our specialized products every step of the way, we've cultivated a unique market niche and are determined to maintain our status as leader and trend-setter in the field of Low Level Laser Therapy.

Photo of Erchonia Laser Health Care

Additional Information

Since 1998, Erchonia Corporation and Rodrigo Neira M.D. have conducted research on adipocytes and continue to achieve groundbreaking results in this field. The fact that both the Erchonia laser used and the application technique itself are patented, is a testament to our dedication to research both at the cellular and clinical levels. Erchonia Corporation met Dr. Neira in 1998 at an Anti Aging seminar.

At that time, Dr. Neira spoke very little English and Erchonia spoke zero Spanish. A dialogue interpreted through his wife Clara Ortiez, M.D. and his brother-in-law began, forming a unique and dynamic partnership from these two unlikely sources.Dr Neira while working with Erchonia Corporation began publishing the study results, the first of which was presented in 2000 at the World Congress on Liposuction. His research on SEM, TEM, and MRI was groundbreaking, showing cell activity here-to-fore unseen. Once the results were published, the abuse started for not only Corporation but also Dr. Neira.

The so-called geniuses’ laughed; stating, “that a low powered laser could never penetrate through the dermis, let alone emulsify the fat below the skin.” Several more publications in the Plastic Surgery Journal, The Aesthetic Surgery Journal, and The American Academy of Cosmetic Surgery journal followed, but there were still many skeptics. Dr. Neira even proved through abdominal on T-1 and T-2 sequences that the Erchonia laser could have an effect on deep fat, but the skeptics kept up their rhetoric.

Even after the millions of dollars spent on clinical and cell research and the peer review of the results, the skepticism increased. Erchonia Corporation, after seeing its friends Rodrigo and Clara take abuse from their peers, decided that they were not going to stand by without a fight. In 2002, Erchonia Corporation decided it would prove the results to the most skeptical and toughest group in the world, The FDA.

Erchonia Corporation met with the board of The American Academy of Cosmetic Surgery (AACS) and asked them if they would provide clinical sites for the study. The Academy members wanted to prove for themselves that the laser actually worked. The AACS decided that they wanted to do a study lazing 1 side of the patient and not the other. During the study the AACS discovered what they called a “systemic effect,” meaning by lazing 1 side of the body, the laser also affected the other side.

The AACS published these results. This obviously was not the best way to do a study and Erchonia Corporation along with its regulatory agent designed a study and met with the FDA on what it would require to get an indication for liposuction through the FDA. The FDA provided comments, the comments were incorporated, the study was submitted to an IRB for approval, and the study was completed. The FDA granted the market clearance in 2004.

Many thanks go to Susan Lim, M.D. from Singapore who presented research that was almost identical to Dr. Neira’s, and expanded upon his findings through cryo SEM, etc. We would also like to thank Arturo Ramirez, M.D. a Plastic Surgeon from Monterey, Mexico who presented his research using cells from an abdominalplasty and through time based microscopy, proving that 90% of the human fat was emulsified after 12 minutes.

We extend our heartfelt gratitude to Dr. Neira, his wife, and their research team for the years of dedicated and innovative research and also for their unwavering belief in Erchonia Corporation and low-level laser technology. However, their greatest strength, in our opinion, was their perseverance through the many years of abuse, doubt, and recrimination, inflicted by the self-promoted so-called geniuses in their profession. Even after Dr. Neira and Erchonia Corporation spent millions of dollars conducting the studies and after having the resulting research verified by three outside independent sources, these naysayers, still refuse to give him the credit he so richly deserves.

Erchonia Corporation would also like to give a special thanks to the following: Robert Jackson, M.D., who although was very skeptical at first, gave the Erchonia laser a try and to this day is one of the greatest advocates of Laser Liposuction™. Doug Dedo, M.D., who was the first person in the US to do low-level laser liposuction and mentions the Erchonia laser to everybody he comes in contact with. Greg Roche,M.D. who's dedication to the laser and research is greatly appreciated. Ed Lack, M.D., who because of his initial skepticism, helped Erchonia Corporation provide some great science. Please take the time to go through this amazing research.

erchonia Corporation took on this project for two reasons, one to prove that low-level lasers (3LT®) can influence pain along with reducing swelling and edema and the second to substantiate our position on depth of penetration. Erchonia Corporation has never agreed with the prevailing “depth of penetration theory,” and has proven through Rodrigo Neira, MD and Erchonia Corporation's ground-breaking research on abdominal MRI, that a 635nM laser could emulsify fat deep into the abdominal fat. (Ref: AACS 2003).

Laser Breast Augmentation patients were asked to participate in a study using real and placebo lasers. Through random selection, half the patients were placed in a control or real laser treated group and the other half placed in the placebo group. The procedure consisted of cutting a half moon in the areola complex (nipple), the muscle was pulled back and a pocket was created on the chest wall. The implant was then put into place and the muscle pulled over the implant. Once in place, the implant was inflated to the desired size and the nipple was then sewed back together.

The medical laser had to deal with the pain of creating the pocket, stretching the muscle to put the implant in and then cutting and sewing the skin back together. Lazed patients were compared to placebo treated patients on a self-reported pain scale of 1 to 100. Patients rated their pain levels throughout the process and when tabulated showed the Erchonia laser to be 77% more effective than the placebo. The phenomenal results of the Laser Enhanced Breast Augmentation™ study has proven through 105 patients that low-level lasers have an effect on pain deep into the body when compared to placebo.

Prior to beginning this study in 2005, it was submitted to the FDA and an IRB for evaluation and approval. The results of the study were submitted to the FDA for market clearance in August 2007. An article depicting the clinical study and results has been submitted for publication and is expected to be published in 2008. An abstract has been provided.

Specialities

There are a number of applications for Erchonia Corporation's groundbreaking laser devices. Due to the great deal of research and study that the Erchonia professionals have completed, the FDA found it necessary to create a new regulatory category of medical devices: NHN Biostimulation lasers.

There are a number of laser applications available on the market, and many being researched every day. These are a few of the more common laser applications in which Erchonia Corporation lasers specialize.

Body Contouring,Erchonia lasers are proven to target and eliminate fat in areas that are difficult to target with regular diet and exercise. The Zerona laser is proven to target these difficult areas and biostimulate the body on the cellular level.

The Erchonia EML laser approved as an addition to traditional liposuction surgery. It is the first and only low-level laser to be given FDA market clearance for use during liposuction. The painless laser treatment is applied prior to liposuction and liquefies the fat. This makes for a much easier removal of fat, and results in less post-op pain and bruising as well as a much shorter recovery time.

Neck and Shoulder Pain,A variety of low level lasers are proven to be effective in reducing and eliminating acute and chronic pain in the neck & shoulders .Many patients find that this solution is a much more effective and immediate alternative to traditional pain medications. Combined with forms of chiropractics and therapy, the Erchonia lasers can help patients lead a normal, active, and healthy life without debilitating pain.

Acne,Currently, there are many acne treatments available in the form of pills, lotions, tonics, chemicals, and more, but Erchonia has developed a new solution with the DERMALASER. This FDA market cleared laser targets the actual type of bacteria that is responsible for causing acne, rather than targeting the skin. This treatment does not lead to irritated skin cells because it attacks the cause of acne at the root.

Rather than spending many months or years on powerful antibiotics, creams, and more, patients can now attach their acne with painless low-level laser treatments.Cold lasers are currently undergoing studies for use against viruses, scars, burns, wound healing, and much more. Though it is a relatively new field of medicine, Erchonia’s commitment to low-level laser treatment has made great advancements for laser technology. The future of medical lasers is certainly bright.